Cellectar Biosciences, Inc.
13 clinical trials · Sponsor
◉ Watch Cellectar Biosciences, Inc.
| Record | Firm | Date |
|---|---|---|
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients (NCT07766421) | Cellectar Biosciences, Inc. | 2026-12-01 |
| Phase 1 Study of CLR 125 in Triple Negative Breast Cancer (NCT07311993) | Cellectar Biosciences, Inc. | 2025-12-05 |
| Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG (NCT05610891) | Cellectar Biosciences, Inc. | 2023-10-01 |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas (NCT03478462) | Cellectar Biosciences, Inc. | 2019-04-30 |
Track Cellectar Biosciences, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.